Type Whole antibody Target CD56 CAS Number 1008106-64-6 | Source Humanized ATC code none ChemSpider none | |
 | ||
Lorvotuzumab mertansine (IMGN901) is an antibody-drug conjugate. It comprises the CD56-binding antibody, lorvotuzumab (huN901), with a maytansinoid cell-killing agent, DM1, attached using a disulfide linker, SPP. (When DM1 is attached to an antibody with the SPP linker, it is mertansine; when it is attached with the thioether linker, SMCC, it is emtansine.)
Lorvotuzumab mertansine is an experimental agent created for the treatment of CD56 positive cancers (e.g. small-cell lung cancer, ovarian cancer).
It has been granted Orphan drug status for Merkel cell carcinoma.
It has reported encouraging Phase II results for small-cell lung cancer.
References
Lorvotuzumab mertansine Wikipedia(Text) CC BY-SA